Epilepsy is a common neurological disorder that poses a serious threat to human physical and mental health, and WHO statistics show that the prevalence of epilepsy ranges from 5‰ to 11.2‰, with at least 50 million people with epilepsy in the world today. Although treated with regular antiepileptic drugs, about 20-30% of subjects still respond poorly to drug therapy and have seizures that are difficult to control effectively, known as drug-refractory epilepsy. Repeated seizures, long-term medication, and social discrimination have a great impact on the quality of life of the subjects. Surgical treatment should be considered early for patients with drug-refractory epilepsy. For patients with epilepsy who cannot be craniotomized for various reasons, or who continue to have seizures after craniotomy, implantable vagus nerve stimulation (Vagus) is the only FDA-approved procedure for electrical stimulation. VNS has the advantages of good seizure control, no craniotomy, no damage to brain tissue and function, low risk, improved quality of life, improved memory, arousal and mood, and has been implanted in more than 110,000 cases worldwide. Although there are many subjects in China, the application of VNS therapy is still very limited, with only a few hundred treatment cases, mainly due to economic factors. Currently, the price of imported stimulators for clinical application is as high as 160,000 RMB, not including the cost of replacing the pulse generator when the battery runs out every few years afterwards, which is a very heavy financial burden for the subjects. In this context, Beijing Pinchi Medical Equipment Co., Ltd. and Tsinghua University have cooperated to develop a domestic neuromodulator with completely independent intellectual property rights to reduce the price of the product, thus bringing the therapy to more subjects in need. Guidelines Age 6-60 years old; intractable epilepsy that has not been effectively controlled by antiepileptic drugs for more than 2 years; more than 6 seizures per month; good physical health except for epilepsy; normal MMSE screening results; subjects or their family members can fully understand the therapy and sign the informed consent form; subjects are compliant and can cooperate to complete the postoperative follow-up The subject is compliant and able to complete post-operative follow-up. Contraindications to surgery: MRI of intracranial occupying lesions; lesions or damage to the vagus nerve itself; coexisting tumors, cardiopulmonary abnormalities, progressive neurological disease, asthma, psychiatric disease, peptic ulcer, insulin-dependent diabetes mellitus, or poor general condition, as determined by the surgeon or anesthesiologist.